Get the Stockscreener App
7.06
0.70%
-0.05
After Hours:
7.09
0.03
+0.42%
Kamada Ltd stock is traded at $7.06, with a volume of 26,482.
It is down -0.70% in the last 24 hours and up +5.37% over the past month.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
See More
Previous Close:
$7.11
Open:
$7.14
24h Volume:
26,482
Relative Volume:
0.34
Market Cap:
$407.23M
Revenue:
$154.57M
Net Income/Loss:
$15.07M
P/E Ratio:
26.15
EPS:
0.27
Net Cash Flow:
$10.92M
1W Performance:
-0.42%
1M Performance:
+5.37%
6M Performance:
-8.90%
1Y Performance:
+15.93%
1-Day Range:
$7.0401
$7.156
1-Week Range:
$6.975
$7.17
52-Week Range:
$5.54
$9.155
Kamada Ltd Stock (KMDA) Company Profile
Compare KMDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KMDA
Kamada Ltd
|
7.06 | 410.12M | 154.57M | 15.07M | 10.92M | 0.27 |
|
ZTS
Zoetis Inc
|
125.82 | 55.71B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.59 | 49.38B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.11 | 44.89B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.21 | 35.96B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
487.25 | 21.36B | 3.08B | 1.24B | 1.07B | 25.61 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | The Benchmark Company | Buy |
| Jul-03-24 | Initiated | Stifel | Buy |
| Feb-02-18 | Initiated | Chardan Capital Markets | Buy |
Kamada Ltd Stock (KMDA) Latest News
Kamada Ltd. (NASDAQ:KMDA) Short Interest Update - MarketBeat
Kamada (NASDAQ:KMDA) Shares Pass Above 50-Day Moving AverageTime to Sell? - MarketBeat
Kamada (NASDAQ:KMDA) Shares Pass Above 50-Day Moving Average – Time to Sell? - Defense World
Kamada (KMDA) price target decreased by 11.86% to 13.26 - MSN
Kamada (KMDA) Stock Analysis Report | Financials & Insights - Benzinga
Kamada Ltd.(NasdaqGS: KMDA) added to NASDAQ Biotechnology Index - marketscreener.com
Is Kamada Ltd. stock affected by interest rate hikesInsider Selling & Long-Term Growth Plans - Улправда
Will Kamada Ltd. stock see insider buyingWeekly Trend Recap & Precise Entry and Exit Recommendations - Улправда
Is Kamada Ltd. stock positioned well for digital economyLayoff News & Fast Exit and Entry Strategy Plans - Улправда
Can Kamada Ltd. stock resist sector downturns2025 Top Gainers & Expert-Curated Trade Recommendations - DonanımHaber
Kamada announces $10M-$14M extension of Canadian supply tender - TipRanks
Can Kamada Ltd. stock rebound after recent weaknessIndex Update & Consistent Return Strategy Ideas - Улправда
Breakout Watch: Is Kamada Ltd. stock positioned well for digital economyJuly 2025 News Drivers & Growth Focused Entry Point Reports - Улправда
Kamada secures $10-14 million Canadian supply tender extension By Investing.com - Investing.com Nigeria
Kamada Ltd. Announces $10 Million to $14 Million Extension of Canadian Supply Tender - marketscreener.com
Kamada Receives Two-Year Supply Extension From Canadian Blood Services for Plasma-Derived Products - marketscreener.com
Kamada Wins $10–$14 Million Extension of Canadian Plasma-Product Tender - TipRanks
Kamada secures $10-14 million Canadian supply tender extension - Investing.com
Kamada (KMDA) announces $10–$14 million extension of Canadian tender - Stock Titan
Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender - GlobeNewswire
Kamada Initiates Clinical Trial for CYTOGAM in Kidney Transplantation - MSN
Kamada shares drop as company halts Phase 3 study of inhaled AAT therapy - MSN
Breakout Zone: How geopolitical tensions affect Kamada Ltd stock2025 Earnings Surprises & Consistent Return Investment Signals - moha.gov.vn
Precision Trading with Kamada Ltd. (KMDA) Risk Zones - Stock Traders Daily
Kamada (NASDAQ:KMDA) Stock Rating Upgraded by Wall Street Zen - Defense World
FY2025 Earnings Forecast for Kamada Issued By HC Wainwright - Defense World
What is HC Wainwright's Forecast for Kamada FY2025 Earnings? - MarketBeat
Sidoti Csr Comments on Kamada’s Q1 Earnings (NASDAQ:KMDA) - Defense World
HC Wainwright Has Bearish Outlook for Kamada FY2026 Earnings - Defense World
Kamada Ltd. Shareholders Approve Key Resolutions at Annual Meeting - TipRanks
Sidoti Csr Predicts Kamada's Q1 Earnings (NASDAQ:KMDA) - MarketBeat
H.C. Wainwright raises Kamada stock price target to $13 on strategic refocus - Investing.com Nigeria
H.C. Wainwright raises Kamada stock price target to $13 on strategic refocus By Investing.com - Investing.com South Africa
Why Is Kamada Stock Trading lower todayKamada (NASDAQ:KMDA) - Benzinga
Kamada to Discontinue Phase 3 Trial of Inhaled AAT: Shares Fall - marketscreener.com
Kamada discontinues Phase 3 inhaled AAT clinical trial - TipRanks
Kamada reiterates FY25 revenue guidance $178M-$182M - TipRanks
Kamada Discontinues Phase 3 Inhaled AAT Trial, Projects Growth in 2026 - TipRanks
Kamada (KMDA) Halts Phase 3 Trial of Inhaled AAT for Alpha-1 Ant - GuruFocus
Kamada reiterates 2025 FY revenue guidance of $178M-$182M - marketscreener.com
Kamada Reiterates 2025 FY Revenue Guidance Of $178M-$182M - TradingView
Kamada stock tumbles after discontinuing Phase 3 Inhaled AAT trial By Investing.com - Investing.com Canada
Kamada stock tumbles after discontinuing Phase 3 Inhaled AAT trial - Investing.com
Kamada (NASDAQ: KMDA) drops inhaled AAT study, reaffirms $178M-$182M 2025 revenue - Stock Titan
Shareholders May Not Be So Generous With Kamada Ltd.'s (TLV:KMDA) CEO Compensation And Here's Why - simplywall.st
Kamada (NASDAQ:KMDA) Share Price Passes Below 200-Day Moving AverageTime to Sell? - MarketBeat
Kamada (NASDAQ:KMDA) Share Price Passes Below 200-Day Moving Average – Time to Sell? - Defense World
Technical Reactions to KMDA Trends in Macro Strategies - news.stocktradersdaily.com
Kamada updates proxy statement ahead of annual shareholder meeting By Investing.com - Investing.com Australia
Kamada updates proxy statement ahead of annual shareholder meeting - Investing.com
Kamada Ltd Stock (KMDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.30%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):